Product image of Meliglix 50 Mg (Sitagliptin) supplied by GNH India

Meliglix 50 Mg

Active Ingredient:
Sitagliptin
Origin:
EU

Meliglix 50 Mg (Sitagliptin)

Sitagliptin, the active ingredient in Meliglix 50 Mg, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as a 50 mg tablet for oral administration. It is used to improve glycaemic control in adults with type 2 diabetes mellitus, often as part of a comprehensive treatment plan that includes diet and exercise.

GNH India supplies Meliglix 50 Mg as a licensed, Good Distribution Practice‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide through regulated channels and supporting customers with documentation, logistics and quality assurance.

Manufacturer / TM Owner

Pharmazac Sa

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Sitagliptin is indicated for the management of type 2 diabetes mellitus, acting on the incretin pathway to regulate blood glucose.
  • Type 2 diabetes mellitus (monotherapy): improves glycaemic control when diet and exercise alone are insufficient.
  • Type 2 diabetes mellitus (combination therapy): used together with metformin or other oral agents to achieve target glucose levels.
  • Type 2 diabetes mellitus (adjunct to lifestyle): supports blood‑sugar management alongside diet and exercise.

How It Works

  • Sitagliptin selectively inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, which degrades the incretin hormones GLP‑1 and GIP. By preventing this degradation, sitagliptin increases circulating incretin levels, thereby enhancing glucose‑dependent insulin secretion and suppressing glucagon release, leading to lower post‑prandial and fasting blood glucose concentrations.

Side Effects

Common Side Effects

  • Nasopharyngitis: mild inflammation of the upper airway.
  • Headache: transient head discomfort.
  • Upper respiratory tract infection: symptoms such as cough and sore throat.
  • Gastrointestinal upset: nausea, abdominal pain or dyspepsia.
  • Dizziness: occasional light‑headed sensation.
  • Arthralgia: joint pain without swelling.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain requiring immediate medical attention.
  • Severe allergic reactions: rash, angioedema or anaphylaxis.
  • Hepatic injury: elevated liver enzymes or jaundice.
  • Bullous pemphigoid: blistering skin disorder.
  • Acute renal failure: sudden loss of kidney function.

Precautions & Warnings

Before initiating therapy, consider the following precautions:

  • Renal function assessment: adjust dose in patients with impaired renal function.
  • Monitor blood glucose: watch for hypoglycaemia when combined with insulin or sulfonylureas.
  • Cardiovascular risk: evaluate in patients with a history of heart failure.
  • Pregnancy and lactation: use only if benefits outweigh potential risks; data are limited.
  • Elderly patients: start at a lower dose and monitor for adverse reactions.
  • Store at ambient temperature: keep below 25 °C, retain in the original packaging, and protect from moisture.

Avoid Interactions

Sitagliptin may interact with several medicines. Review the following categories:

Major Interactions (Avoid)

  • Concomitant use with insulin or sulfonylureas: increased risk of hypoglycaemia.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise sitagliptin plasma concentrations.

Moderate Interactions (Monitor Closely)

  • Diuretics such as furosemide: may reduce antihyperglycaemic efficacy.
  • Rifampin: can lower sitagliptin levels, potentially reducing effectiveness.
  • ACE inhibitors: monitor renal function and electrolytes.
  • Warfarin: periodic INR monitoring is advised.

Frequently Asked Questions

Meliglix 50 Mg contains sitagliptin, a DPP‑4 inhibitor prescribed to improve blood‑sugar control in adults with type 2 diabetes mellitus, usually as part of a regimen that includes diet, exercise and possibly other antidiabetic agents.

Sitagliptin blocks the enzyme dipeptidyl peptidase‑4, which normally breaks down the incretin hormones GLP‑1 and GIP. By preserving these hormones, the drug enhances insulin release after meals and reduces glucagon production, helping to lower both post‑prandial and fasting glucose levels.

The prescribed dose is determined by the treating clinician based on the patient’s clinical condition, renal function and other medications. In many treatment protocols, a 50 mg tablet taken once daily is a common starting point, but the exact regimen should follow the prescriber’s instructions.

Safety data for sitagliptin in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and only under the guidance of a qualified healthcare professional.

Enquiries can be submitted through the product page on gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Sitagliptin belongs to the DPP‑4 inhibitor class, offering glucose‑dependent insulin secretion with a low risk of hypoglycaemia compared with sulfonylureas. Unlike metformin, it does not affect gastrointestinal absorption, and it can be combined with many other agents, providing flexibility in treatment plans.

Store the tablets at ambient temperature, preferably below 25 °C, in the original blister pack or container. Keep them away from moisture, direct sunlight and excessive heat to maintain potency throughout the shelf life.

Meliglix 50 Mg is taken orally, with or without food, as a whole tablet. Swallow the tablet whole with a glass of water; do not crush or chew it, and follow the dosing schedule prescribed by the healthcare provider.

The most concerning adverse events include acute pancreatitis, severe allergic reactions such as anaphylaxis or angioedema, and rare skin disorders like bullous pemphigoid. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, or swelling.

Individuals with a known hypersensitivity to sitagliptin or any component of the tablet should avoid it. It is also contraindicated in patients with severe renal impairment unless dose‑adjusted, and it should be used with caution in those with a history of pancreatitis.

Medically reviewed by

Dr. Shweta Ashok More

M.Pharm (Quality Assurance), Ph.D. (Medicinal Chemistry), GNH India Pharmaceuticals Limited · Reviewed 9 Sep 2026

Published by GNH India Pharmaceuticals Limited · Last updated

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT